ChromaDex Corp CDXC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDXC is a good fit for your portfolio.
News
-
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
-
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
-
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
-
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
-
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
-
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
-
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
Trading Information
- Previous Close Price
- $3.40
- Day Range
- $3.36–3.51
- 52-Week Range
- $1.25–4.65
- Bid/Ask
- $3.42 / $3.52
- Market Cap
- $255.30 Mil
- Volume/Avg
- 147 / 343,447
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.04
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 106
- Website
- https://www.chromadex.com
Comparables
Valuation
|
Metric
|
CDXC
|
SCLX
|
VSBC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 3,629.76 |
Price/Book Value | 8.93 | — | 1,908.62 |
Price/Sales | 3.04 | 2.65 | 664.53 |
Price/Cash Flow | 101.88 | — | 2,904.34 |
Price/Earnings
CDXC
SCLX
VSBC
Financial Strength
|
Metric
|
CDXC
|
SCLX
|
VSBC
|
|---|---|---|---|
Quick Ratio | 1.57 | 0.15 | 4.32 |
Current Ratio | 2.40 | 0.19 | 4.33 |
Interest Coverage | — | −106.04 | — |
Quick Ratio
CDXC
SCLX
VSBC
Profitability
|
Metric
|
CDXC
|
SCLX
|
VSBC
|
|---|---|---|---|
Return on Assets (Normalized) | −0.35% | −106.47% | 42.38% |
Return on Equity (Normalized) | −0.68% | — | 65.38% |
Return on Invested Capital (Normalized) | −2.67% | −1,960.39% | 55.23% |
Return on Assets
CDXC
SCLX
VSBC
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zmzrhstk | Cwwwk | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wrhghldkv | Fmzntc | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jlrqrclwn | Qlxjsvj | $97.8 Bil | |
MRNA
| Moderna Inc | Rpcgmzps | Hqfk | $38.8 Bil | |
ARGX
| argenx SE ADR | Wchgwzrs | Kzvpk | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Bfymzghzb | Hpjsn | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nfdrjtjs | Bksjv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Tdjmqgxq | Rjmrptk | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dfrplsllh | Sgqkt | $12.5 Bil | |
INCY
| Incyte Corp | Ghhkkxjh | Tqtnnx | $11.5 Bil |